Home
News
Society
Media
Health
Spirit
Ecology
Animals
Mind
Science
Business
Destiny
Aliens
Misc
Action
Projects
Contact
       
 

Publications on Cancer on the Theme of Tumour Destruction by Disrupting Energy Metabolism
Robert Jones MA PhD

 
Publications by Robert Jones on tumour destruction using Phenergan® to disrupt energy metabolism of cancer cells.
 
If you choose to follow this treatment program, we advise that you inform your doctor or healthcare practitioner. This protocol is presented here for interest only. If you are unwell, please seek professional medical advice.
 
*               *               *
 

  1. Jones GRN. Cancer: restriction of chemical energy by fatty acids as the common pathway whereby various anti-tumour procedures selectively damage malignant cells in situ. Med Hypoth 1976; 2: 50-54.

  2. Jones GRN. Cancer: energy uncoupling as a primary event in endotoxin-induced necrosis of the S180 sarcoma in situ. Biochem Soc Trans 1977; 5: 214-16.

  3. Jones GRN. The selective induction of cellular damage within neoplasia in situ: a putative role for sympathomimetic agents. Med Hypoth 1976; 3: 215-16.

  4. Jones GRN, Winter H, Merkel R. Alterations in the adenine nucleotide pattern as a sensitive means of assessing injury in a solid tumour. Hoppe-Seiler Zeits Physiol Chemie 1978; 359: 1102-103.

  5. Jones GRN, Hummel J, Mahr J, Merkel R. Interference with energy production in the S180 sarcoma caused by isoproterenol and endotoxin. Naunyn-Schmiedeberg Arch Pharmacol 1979; 307 (Supplement): R18.

  6. Jones GRN. Early mitochondrial damage in the induction of haemorrhagic necrosis in the Crocker sarcoma (S180) by endotoxin. J Cancer Res Clin Oncol 1979; 93: 245-54.

  7. Jones GRN. Early cutback in chemical energy production in the Crocker sarcoma (S180) undergoing haemorrhagic necrosis as a result of endotoxin administration. J Cancer Res Clin Oncol 1980; 96: 53-64.

  8. Jones GRN, Baum R, Merkel R, Schwarz M. Disturbance in vivo to energy production caused by hormones and sympathomimetics in the S180 sarcoma, with consequent drug-induced necrosis. Biochem Soc Trans 1980; 8: 105.

  9. Jones GRN. Prevention of drug-induced upset to energy production in the S180 sarcoma by inhibition of prostaglandin synthetase. Biochem Soc Trans 1980; 8: 106-107.

  10. Jones GRN, Ellis, R, Frohn MJN. Drug-induced interference with energy metabolism in the S180 sarcoma: a new principle in the production of selective tumour injury. Oncodev Biol Med 1981; 2: 155-64.

  11. Jones GRN. A new approach to the selectivity of anti-tumour action. Brit J Cancer 1982; 45: 638.

  12. Jones GRN, Miller S, Scobie-Trumper P. Resensitization of drug-resistant S180 tumour cells with ergotamine. Biochem Soc Trans 1982; 10: 502-503.

  13. Jones GRN. Interference with energy production as a means of causing injury to a human pancreatic carcinoma. Oncology 1983; 40: 259-62.

  14. Jones GRN, Frohn MJN. An injurious effect of chlorpromazine in the murine S180 sarcoma (var CB) and its relevance to cancer treatment. Biochem Soc Trans 1984; 12: 679-80.

  15. Jones GRN, Frohn MJN, Beckett AH. Liminal therapy: a strategy for the complete and selective destruction of malignant tissue in situ. Med Hypoth 1984; 15: 349-59.

  16. Jones GRN, Thatcher R. A comparison of the effects of the optical isomers of isoproterenol on energy metabolism in a mouse sarcoma. Experientia 1985; 41: 1045-46.

  17. Jones GRN. Cancer therapy: phenothiazines in an unexpected role. Tumori 1985; 71: 563-69.

  18. 18. Jones GRN. Free radicals in immunological killing: the case for tumour necrosis factor (TNF). Med Hypoth 1986; 21: 267-71.

  19. Jones GRN. Cancer therapy at the crossroads: which direction for the future? Physiol Chem Phys Med NMR 1991; 23: 217-20.

  20. Jones GRN. Cancer destruction in vivo through disrupted energy metabolism. I. The endogenous mechanism of self-destruction within the malignant cell, and the roles of endotoxin, certain hormones and drugs, and active oxygen in causing cellular injury and death. Physiol Chem Phys Med NMR 1992; 24: 169-79.

  21. Jones GRN. Cancer destruction in vivo through disrupted energy metabolism. II. Lipid peroxidation and cell death: drug resistance as a consequence of reversible cellular injury. Physiol Chem Phys Med NMR 1992; 24: 181-94.

  22. Jones GRN. Cancer destruction in vivo through disrupted energy metabolism. III. Spontaneous drug resistance, selectivity of antineoplastic action, and strategies for intensifying tumour injury. Physiol Chem Phys Med NMR 1992; 24: 195-212.

  23. Jones GRN. Successful cancer therapy with promethazine: the rationale. Med Hypoth 1996; 46: 25-29.

  24. Jones GRN. Coagulative necrosis: the forgotten way to die. Biochem Soc Trans 1998; 26: S321.

  25. Jones GRN. Treatment of cancer with low-dose phenothiazines, with special reference to promethazine. In: Non-Antibiotics: a new class of unrecognised antimicrobics (eds Chakrabarty AN, Molnar J, Dastidar SG) pp.79-93. Nat Sci Science Comm (NISCOM), New Delhi, India (1998).
 
Copyright © 2000 Robert Jones
Reproduced here with kind permission
 
This article is for interest only. If you are unwell or have a medical condition, please seek professional medical advice.
 
 
**ONLINE INDEX**
Introduction
New Approach
Background
TREATMENT
Notes
Publications
 
Robert Jones MA PhD read Natural Sciences at Cambridge University. Entering cancer research in 1959, he was awarded a PhD in pathology in 1966. He has held appointments at the Royal College of Surgeons and London medical schools. He has worked in the Universities of Munich and Tubingen and at the German Cancer Research Centre at Heidelberg.
 
Although cancer has been his major professional interest, Dr. Jones has published original work on histochemistry, quantitative analysis, reagent design and synthesis, organ transplantation and toxicology.
 
Dr. Jones' biggest breakthrough has been finding a way, using an over-the-counter medication called Promethazine (Phenergan) along with specific health supplements, to alter cancer cells' mitochondrial energy metabolism so that toxins are produced that kill off just the cancer cells. This is an effective, selective and inexpensive cancer treatment that allopathic medicine does not want you to know about.
 
If you are interested in knowing more about this cancer treatment, please use the link menu above. Dr. Jones has also written a book called In the Darker Shadow of Science covering this remarkable cancer treatment and the negative reaction to it from other doctors. This book is unfortunately out of print at the moment but a new revised edition should be published shortly.
 
Dr. Jones can be contacted at crackcancer@hotmail.com.
 
Robert Jones' book
 
     
      © EnergyGrid Magazine